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Toxicology has been an active research field for many decades, with 
academic, industrial and government involvement. Modern omics and 
computational approaches are changing the field, from merely 
disease-specific observational models into target-specific predictive 
models. Traditionally, toxicology has strong links with other fields 
such as biology, chemistry, pharmacology and medicine. With the rise 
of synthetic and new engineered materials, alongside ongoing 
prioritisation needs in chemical risk assessment for existing 
chemicals, early predictive evaluations are becoming of utmost 
importance to both scientific and regulatory purposes. ELIXIR is an 
intergovernmental organisation that brings together life science 
resources from across Europe. To coordinate the linkage of various 
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life science efforts around modern predictive toxicology, the 
establishment of a new ELIXIR Community is seen as instrumental. In 
the past few years, joint efforts, building on incidental overlap, have 
been piloted in the context of ELIXIR. For example, the EU-ToxRisk, 
diXa, HeCaToS, transQST, and the nanotoxicology community have 
worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms 
and activities. In 2018, a core group of interested parties wrote a 
proposal, outlining a sketch of what this new ELIXIR Toxicology 
Community would look like. A recent workshop (held September 30th 
to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap 
and a shortlist of limited investment-high gain collaborations to give 
body to this new community. This Whitepaper outlines the results of 
these efforts and defines our vision of the ELIXIR Toxicology 
Community and how it complements other ELIXIR activities.
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Introduction of the ELIXIR Toxicology Community
Toxicology as a field tries to understand the negative consequences that may arise from the interactions of chemicals
with living organisms. In this ELIXIR (European life-sciences Infrastructure for biological Information)1 Community,
the focus will be primarily the protection of human health. There are a number of both chemical and biological
“interoperability” issues key to the toxicology field that translate into data interoperability issues. These include the
connection between the action and activity of a particular chemical compound to its effective amount available at a
biological target (the link between toxicodynamics and toxicokinetics). Typically this is also a link between biological
data analysis (including large-scale multi-omics) and kinetic modelling. Other examples include interactions between a
compound and its target (a protein, nucleic sequence or membrane structure for instance). This is primarily based on the
interplay between chemistry (the chemical structure and, for example, its related properties in terms of functional groups,
charge, shape and related binding affinity) and biochemistry (like biomolecular 3D structures). Also, mixture toxicity
needs to be considered as combinations of chemicals with synergistic or antagonistic behaviour, or a combination thereof.
While chemicals with similar modes of action may act in terms of concentration addition, those with different modes may
rather act according to independent action.2,3 Substances with low toxicity may interact in concentration addition rather
than as excess toxicity drivers of one compound. Often there is a need to translate the knowledge about one compound
into knowledge about other compounds, where approaches like quantitative structure-activity relationships (QSARs)
help to elucidate this knowledge and predict required property and toxicity, and in more general when “read-across
approaches” come into play that are based on chemical data only, biological data only, or are hybrid.4,5 These again need
detailed information about the relationships between related chemical compounds, specific properties and toxicological
endpoints and, when considering chemical-biological interactions, details regarding both the chemical structures and
adequate descriptions of the biological targets. Since toxicological endpoints can be represented in a myriad of ways,
the toxicological effect data are often scattered over multiple repositories and databases hosting different types of
data; i.e. chemical structures, toxicity data (in vivo and in vitro), biological target details, and omics data. This itself
is not a problem, but the separation and segregation make the data difficult to find and to connect. Currently, many of
these deposition databases (where datasets can be archived) do not provide adequate descriptions regarding typical
toxicological study designs and parameters, quality control, data acceptance criteria, or even clear identification of the
compounds tested. This all adds to the need for an adequate FAIRification process, to make toxicology data more
Findable, Accessible, Interoperable and Reusable (FAIR - see Go-FAIR).6,7
The field of toxicology would certainly benefit from clear, standardized guidelines for data capture, approaches to
integrate and connect across multiple databases, clear data licensing for these data repositories, and tools that support
accessing the data (as being developed by the ELIXIR Converge data brokerage work). Existing study capture tools can
be extended with templates defined for toxicology, which end up in a central place (e.g.Biosamples8) with links to omics
and other data distributed over technology-specific deposition databases and BioStudies.9 Relevant portals (e.g. FAIR-
sharing.org10,11) should then be able to identify these studies, also linking to existing but scattered toxicology databases.
Risk assessment, consisting of hazard identification, characterisation and risk evaluation in relation to exposure, involves
expert opinions based on discussions and data interpretation. Streamlining this process is important also because of the
huge number of chemicals known and produced in chemistry, biotechnology or food production, with over 350,000
chemicals documented on the global market.12 However, expert evaluation is and will remain crucial and calls for
extensive data provenance both for the actual data (howwas it measured, where was it published, whom to give credit for
it), and for the risk assessments themselves. Interestingly this process stumbles on problems and solutions that havemuch
in commonwith other fields, where part of the data need to be hidden and other parts can be publicly accessed, as observed
in pilot approaches in genetics, or patient data repositories.
Toxicology, while established as discipline, is also rapidly developing in areas, where, for example, new molecular
methods to describe the adverse outcome of exposure to a toxic substance are not yet fully established. This offers
opportunities for integration in systems biology approaches building onmolecular pathway descriptions that benefit from
modern network biology approaches. Compound profiling, where, for example, using omics methods to characterize the
effect of compounds on cells, are generally useful for categorizing compounds, or for the development of predictive
pathwaymodels. For such studies, the availability of high-quality annotations for compounds is of paramount importance
to enable the use of omics profiles in toxicology.
Toxicology is also an applied field. There are important applications of toxicity tests in the regulatory field and large
amounts of data are collected for that purpose, often for different (governmental) agencies. Making this data more
Findable and Reusable is often seen as an important way to reduce both animal testing and the cost of registration of
new compounds. If some data is not available to the public due to ownership by companies or other constraints, indexes
should be developed to enable the use of this data in an aggregated form (such as the SPIN index of the Swedish
Chemicals agency (KEMI) and other Nordic chemical agencies). Typically, regulatory use requires very precise and rigid
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descriptions of protocols, including reporting methods. On the other hand, better insights into the toxicological
mechanisms, including interactions between chemicals, benefit from more innovative research methods (e.g. single-
cell omics, induced stem cell applications, imaging methods) and from creative development of new analysis methods.
While it is beneficial to combine results from both types of approaches (termed New Approach Methods (NAM) in the
regulatory field), the corresponding interoperability issues are often quite different.
User community
Europe is steadily increasing demands on the risk assessment of chemicals, drugs, cosmetics ingredients and nanomater-
ials to lead to safer products, resulting in a strong toxicology research community with sub-communities in, for example,
the drug development, environmental, nanomaterial and rare-disease areas. Recent changes in European law for animal
testing and new demands for testing of lower-volume chemicals and nanomaterials have triggered large-scale research
into alternative testing approaches. These activities not only produce new biological and mechanistic insights, but also
large amounts of new data, which have to be managed and shared for re-usage to avoid unnecessary duplication of
experiments and, in thisway, reduce animal testing. The goal is that the combination of data from integrated in vitro and in
silico approaches will support (ultimately personalized) risk/benefit health analysis, safer drug innovation with fewer
needs to withdraw after registration, a fact-based perception of chemical safety, safe-by-design nanomaterials and
sustainable and safe economies.
The European Union supports toxicological and risk assessment projects with various funding programs. Recently, large
collections of data have been released, resulting from research clusters, such as SEURAT-1,13 the EUNanoSafety Cluster
(NSC) with NANoREG, EU-ToxRisk,14 the NORMAN Network, and the EU Innovative Medicines Initiative (IMI)
funded projects related to drug toxicology, including eTOX,15 eTRANSAFE,16 and Eurion.17 Data from these and other
projects are becoming available, sometimes as Open Data (e.g.NANoREG) and sometimes as FAIR data. An example of
the latter is EuropeanREACHdata, which has recently beenmade FAIR by theCefic-LRI-funded project AMBIT-LRI.18
Furthermore, the FAIRplus project is collaborating with eTOX on making their data more FAIR, and the new Precision
Toxicology will develop a data commons following the FAIR principles.
However, there are a few opportunities for data handling that need to be taken.19,20 Recent studies show how powerful
the combination of toxicology information and omics data is,21,22 but to be able to obtain the statistical significance to
draw these conclusions, data from the US and Japan had to be combined. In contrast to large data sets like DrugMatrix,23
ToxCast/Tox21,24 and TG-GATEs25 from these countries, data from European projects is often not sufficiently
integrated. Luckily, there are signs that the community is going in the right direction, e.g. the aforementioned data
integration by diXa,26 NANoREG and REACH.27With respect to the European Chemical Industry, various authors have
been involved in other Cefic-LRI activities related to data management (AIMT-3, AIMT-4).
In addition, the eTOX project28 has established data integration approaches e.g. to enable the development of QSARs
relating chemical structures to in vivo toxicopathological outcomes. As such, the project also delivered databases and
approaches to ontology development, text mining approaches, and approaches for prediction of drug metabolism and
pharmacokinetic features. Moreover, in 2017 the Organisation for Economic Co-operation and Development (OECD)
performed an online survey underscoring the fact that data integration for safety is of global concern for ultimate risk
assessment. The purpose of the resulting knowledge base is the integration of eCHEMportal (The Global Portal to
Information on Chemical Substances29), IUCLID (International Uniform ChemicaL Information Database30), and
OECD’s QSAR Toolbox31 supporting the development of Adverse Outcome Pathways and associated infrastructures
(AOP-Wiki).32 Despite these positive developments, the ‘data integration struggle’ from various perspectives (omics,
computational chemistry and more ‘conventional’ toxicological data within REACH and pharmaceutical industry
setting) remains a challenge.
Roadmap
The above initiatives are mainly driven by user communities themselves: chemical industry, funding agencies,
pharmaceutical companies, governmental agencies and organisations such as Member State organisations, the OECD
and non-governmental organisations (NGOs). ELIXIR can contribute strongly to the existing infrastructure projects from
a cheminformatics and bioinformatics perspective, providing tools and guidelines, linking and harmonizing the ongoing
activities, serving the toxicology users.
For future risk assessment paradigms solely based on human-derived models, and in this way of higher relevance
for human adverse effects,33 various data types will need to be integrated into and cross the conventional boundaries
of risk assessment. This involves external exposure assessment (e.g. via workplace or environmental modelling
and measurements34,35), internal exposure characterisation (ADME-TK (absorption, distribution, metabolism, and
excretion - toxicokinetics) e.g. via modelling and biomarker-based detection), toxicodynamics on a molecular level,
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and cell and systems biology. In this way, more data-driven mechanism-based evaluations and supporting data can
integrate into regulatory risk assessment. There will not only be more but also more diverse data as e.g. internal exposure
data may be inferred from biomonitoring data and/or physiologically-based toxicokinetic modelling to estimate target
dose available at the active sites involved in the molecular initiating events of Adverse Outcome Pathways (AOPs).
Another relevant topic is the concept of the exposome,36–38 which aims at characterising lifetime exposure (not only to
chemicals in the narrowest sense, but also dietary components, lifestyle factors, environmental exposures, etc) in relation
to health outcome. Often, vulnerable periods of life (infancy, childhood, and old age) are investigated, and the evaluation
also integrates epidemiology. This is one clear demonstration of the trend that the previously distinct areas of toxicology,
drug and product design and personalized/precision medicine39 but also environment and health and epidemiology are
moving closer together. Data sharing will be increasingly necessary across these disciplines. High throughput data
analysis in exposomics, for instance, shares many parallels with metabolomics and other higher level omics analyses,
with an added layer of chemical complexity on top.38
The toxicology community is large and well established. The current list of proponents of an ELIXIR Toxicology
Community only reflects a subset of a much larger community with a lot of commitments to, and activities around open
collaboration. It has clear omics, knowledge management and data infrastructure needs to accommodate the increasing
wish to predict toxicology without animal testing (e.g. in SEURAT-1, EU-ToxRisk, eTOXOBERON40). Foreseeing this
need for better infrastructures, the community has previously contacted ELIXIR for collaboration. Various domain-
specific projects exist that service the toxicology communitywith computational and database knowledge (OpenRiskNet,
NanoCommons) that can translate ELIXIR knowledge to the respective communities. These infrastructure projects are
the successors of research projects focusing on data management, including diXa,26 ToxBank41 and eNanoMapper.42
To benefit the research community, small andmedium-sized enterprises (SMEs) and larger industry, and to enable further
future support to regulatory applications and upcoming calls (e.g. Green Deal43,44), we need to reach an inclusive
ecosystem of data, evaluation and modelling tools. The current separate consortia from different toxicity-related and
neighbouring disciplines already work towards data and knowledge that is FAIR.6 After all, these aspects are essential to
efficiently assess the risk of new compounds and materials, as well as combined risks of current stressors (e.g. under the
exposome concept). To further accelerate these activities, more toxicology-related data and knowledge need to be linked,
such as on physiologically based toxicokinetic (PBTK) modelling, biological pathways describing affected metabolism
and cell biology processes, metabolism, metabolic models andmetabolism predictions, drug-response, omics (biological
identity), chemical structures and associated metadata (use, hazard, transformations), QSARs, AOPs, REACH dossiers,
etc. Simultaneously, an extension towards the human (preclinical toxicology) discipline should be initiated, in which
exposure data are combined with internal exposure and early biomarkers of effect data (e.g. from the European Human
Biomonitoring Initiative (HBM4EU)45 and environmental data from NORMAN46,47) towards pathways of toxicity.
Interoperability with the standardization efforts of clinical research by CDISC is important.
However, to reach such interoperable toxicology, resources need to be better integrated. Despite the work of many
projects, their FAIR features can still be improved and applying newly developed FAIR metrics will help steer this.48
Even though there is overlap in content with existing ELIXIR Communities (Table 1, key demands specifically fostering
the integration for interoperable toxicology and risk assessment include the following roadmap19,20):
• chemical structure interoperability challenges (e.g. links to ELIXIR Metabolomics Community49)
• metadata, open standards (e.g. links to ELIXIR Interoperability Platform, and TeSS50)
• continued ontology development (e.g. links to ELIXIR Interoperability Platform and Ontology Lookup Service)
• interoperable computation (e.g. links to the Galaxy51 and bio.tools52 communities)
• interactions with other ELIXIR Core Data Resources (e.g. Ensembl and Europe PMC)
• interactions with other communities, including nanomedicine and health
• deployment of existing tools and modelling approaches on the ELIXIR Compute infrastructure (also allowing
future growth towards risk estimations needing Monte Carlo approaches)
• integration of ELIXIR AAI
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• InChI implementation for small molecule data
• Spectral database functionality (open implementations)
The concrete steps forward proposed in this roadmap include:
1. Leverage from open solutions (models, ontologies, educational material, standards etc) developed by past and
ongoing toxicology and ELIXIR projects
2. Connect more closely with the core ELIXIR resources (FAIR data, database interoperability, etc), strengthen
and connect the inclusive communities that have evolved over the past few years (OpenTox, eNanoMapper,
diXa, OpenRiskNet, NORMAN) and older communities like the Federation of European Toxicologists &
European Societies of Toxicology (EUROTOX), the Society of Environmental Toxicology and Chemistry
(SETAC) and European Environmental Mutagenesis and Genomics Society (EEMGS, formerly known as
EEMS)
3. Develop open community standards to support common interest (ontologies, APIs, data formats, deposition
databases and publication recommendations)
Table 1. Overlap of the proposed ELIXIR Toxicology Community with ELIXIR platforms and communities.
Overlap
Platforms
Tools Semantic annotation of services (e.g. bio.tools52). Alignment with
BioContainers62 to make toxicology reproducible and redeployable
(e.g. OpenRiskNet)
Data BioStudieswas co-developed by the CHEMBL-EBI team, andbuilds on
ArrayExpress,63 an ELIXIR CoreData Resource. Better adoption of the
core resources. Sharing toxicology workflows on WorkflowHub
Compute ELIXIR Authentication and Authorisation Infrastructure (AAI) is used
by OpenRiskNet. Better and more sustainable compute
infrastructure reuse of core elements (ELIXIR AAI,modelling toolsets)
Interoperability FAIR and Research Data Management (RDM) standards have already
been adopted by various projects. Registries of toxicology tools need
integration with FAIRsharing; There is a huge identifier mapping
service need (also for ontology mapping and chemical (sub)
structures), CommonWorkflow Language (CWL)69 as interoperability
for workflow, and standardized data exchange formats like the
Investigation-Study-Assay (ISA) standard.64
Training Bioschemas annotated tutorials. Several projects have training tasks
that could be added to TeSS, already partially automated.
Communities
3D-bioinfo & Intrinsically Disordered
Proteins (IDP)
Structural information about molecular actions of toxic compounds,
molecular initiating events in AOPs
Galaxy Application Programming Interface (API) standards and ontological
annotation of APIs
Marine Metagenomics Ecotoxicology data reflects effects on populations of species
Plant Sciences Ecotoxicology data reflects effects of toxicants on plants
Metabolomics Toxicants Chemical identifiers, data standards, data repository,
common resources
Proteomics Data standards and repository for proteomics data
Microbial Biotechnology Chemical transformations in biological systems of toxicants
Federated Human Data & Human Copy
Number Variation Community
Federated search, phenotype and genotype data
Rare Diseases Shared biological pathways and interaction effects between rare
diseases and exposure of toxicants
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Specifically, we will continue to grow the list of involved toxicology research groups, projects, and ELIXIR Node
activities. This Community has already held a joint meeting to select the key priorities and use cases (see Tables 2 and 3),
resulting in this positioning paper. The ELIXIR Toxicology Community will continue to expand and search for
contributors with relevant expertise as the community and activities mature. By bootstrapping from Open Science
approaches developed in aforementioned projects (e.g. Open PHACTS53), the new Community will focus on mutual
benefit, an open and inclusive community, solving practical community problems. The goal is not to design domain-
specific approaches, but a pragmatic approach that provides FAIR and open tools from the start, allowing all toxicology
and neighbouring communities to benefit from these harmonized solutions. The inclusive community will involve the
existing sub-communities in pharmaceuticals, e.g. from eTOX, transQST,54 and eTRANSAFE,16 cosmetic ingredients,
e.g. from SEURAT-1, high and low-volume chemicals, e.g. from HBM4EU and soon from Horizon Europe Partnership
for the Assessment of Risk from Chemicals (PARC),47 or from different Cefic-LRI (Lang-Range Research Initiative)
projects, and nanomaterials, via the NanoSafety Cluster, building on shared needs and community solutions and strongly
aligned to other ELIXIR communities. Open licensing and interfaces (ontologies, standards, formats) will encourage new
solutions and collaborations, which will be accessible to any organisation and every project within and outside Europe.
Thiswill allow close interoperability with toxicology communities outside Europe that also use open approaches, while at
the same time allowing compatibility with closed approaches too. This dual model has been demonstrated successfully in
recent projects. A prioritized roadmap is essential; the label “ELIXIR Community” would enable us to set priorities at a
level above the individual projects. Existing components that will give this Community an initial boost, include, software
(e.g. AMBIT with OpenTox API55), databases (e.g. diXa, eNanoMapper, AMBIT-LRI, NORMAN-SLE, MassBank),
ontologies (e.g. the eNanoMapper ontology,56 AOP ontology57), interoperability concepts (e.g. annotation of OpenAPIs,
in collaboration with bio.tools, semantic structural searches with IDSM), teaching/education material (Bioschemas
annotation of outreach activities, in collaboration with TeSS), and virtual infrastructures (e.g. OpenRiskNet Virtual
Research Environment and the NORMANDigital Sample Freezing Platform). However, each of these approaches would
benefit from integration in the ELIXIR Platforms (see examples in Table 1) and with Core and National Resources.
Various existing ELIXIR Communities need similar solutions, e.g. for chemical structure handling, toxicology needs
proteomics and metabolomics, toxicology involves human data, and ecotoxicology has significant impact on crops and
health.
The following projects have been adopting and integrating FAIR toxicology concepts, but need integration with ELIXIR
Platforms and Communities: eTOX, NanoCommons (NanoSafety Cluster), EU-ToxRisk, OpenRiskNet, OpenTox
Foundation, Open PHACTS Foundation, and the diXa platform. Many other projects have a specific scientific focus
but also need integration and some will work on the FAIR concepts. A non-exhaustive list is ACEnano, SmartNanoTox,
HeCaToS, NewGeneris, EnviroGenoMarkers, EXPOsOMICS, HELIX, ASAT,58 PATROLS, and HEALS, as well as
new projects e.g. new Horizon 2020 projects RISK-HUNT3R and HARMLESS and the new Horizon Europe project
PARC. Companies and organisations will profit from this Community either as users or as providers of services on top of
the infrastructure, including ECHA (FI), Edelweiss Connect (CH), IdeaConsult Ltd. (BG), Misvik Biology (FI), TNO
(NL), Seven Past Nine (SI), and the Swedish Academic Consortium for Chemical Safety (SwACCS, SE). Industries
showed a strong interest in toxicology, demonstrated by their activities: Cosmetics Europe was participant in the
Table 2. Examples of existing and anticipated collaboration.
Existing collaboration/Reuse Anticipated collaboration
Tools Semantic annotation of services
(e.g. bio.tools)
Alignment with BioContainers of toxicology
workflow efforts (e.g. OpenRiskNet)
Data diXa was co-developed by the CHEMBL-EBI
team, and builds on ArrayExpress an ELIXIR
Core Data Resources
Better adoption of these Resources
Compute Better and more sustainable compute
infrastructure reuse of core elements (ELIXIR
AAI, modelling toolsets)
Interoperability FAIR and RDM standards have already been
adopted by various projects
Registries of toxicology tools need
integration with FAIRsharing; There is a huge
identifier mapping service need (also for
ontology mapping and chemical (sub)
structures)
Training Bioschemas annotated tutorials Several projects have training tasks that could
be added to TeSS, already partially
automated
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SEURAT-1 cluster; chemical industries (Nanotechnology Industries Association) are participant of the NSC; chemical
branch organisation (Cefic) funds LRI projects around toxicology; pharmaceutical industries funds toxicology research
via IMI projects like eTOX, eTRANSAFE, and Open PHACTS. The Research Data Alliance (RDA) organized a
workshop recently about integration of toxicogenomics resources,59 and collaboration with international organizations
has already been establishedwith, for example, the CompToxChemicals Dashboard team of theUSEPA60 and PubChem
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